Mesenteric panniculitis: Difference between revisions
Ostermayer (talk | contribs) (Prepared the page for translation) |
Ostermayer (talk | contribs) (Prepared the page for translation) |
||
| Line 1: | Line 1: | ||
<languages/> | <languages/> | ||
<translate> | <translate> | ||
==Background== | ==Background== | ||
| Line 7: | Line 8: | ||
*A rare, benign, and chronic fibrosing inflammatory disease that affects the adipose tissue of the mesentery (of the small intestine and colon)<ref name="Issa" />. | *A rare, benign, and chronic fibrosing inflammatory disease that affects the adipose tissue of the mesentery (of the small intestine and colon)<ref name="Issa" />. | ||
*Occurs independently (specific cause unknown) or in association with other disorders<ref name="Issa" /> | *Occurs independently (specific cause unknown) or in association with other disorders<ref name="Issa" /> | ||
| Line 12: | Line 14: | ||
*[[Special:MyLanguage/Abdominal pain|Abdominal pain]] | *[[Special:MyLanguage/Abdominal pain|Abdominal pain]] | ||
| Line 21: | Line 24: | ||
*Regional increase in mesenteric fat density on abdominal CT (i.e. “misty mesentery”) | *Regional increase in mesenteric fat density on abdominal CT (i.e. “misty mesentery”) | ||
**May be confirmed by surgical biopsy | **May be confirmed by surgical biopsy | ||
| Line 31: | Line 35: | ||
*Chronic treatment includes workup of underlying etiology and consideration of medical therapy for severe/protracted disease (e.g. corticosteroids, cyclophosphamide, or azathioprine) | *Chronic treatment includes workup of underlying etiology and consideration of medical therapy for severe/protracted disease (e.g. corticosteroids, cyclophosphamide, or azathioprine) | ||
| Line 36: | Line 41: | ||
*Outpatient | *Outpatient | ||
| Line 41: | Line 47: | ||
*Overall prognosis is usually good and recurrence seems to be rare<ref name="Issa" /> | *Overall prognosis is usually good and recurrence seems to be rare<ref name="Issa" /> | ||
| Line 54: | Line 61: | ||
[[Category:GI]] | [[Category:GI]] | ||
</translate> | </translate> | ||
Latest revision as of 23:45, 4 January 2026
Background
- Also known as sclerosing mesenteritis, mesenteric lipodystrophy, mesenteric sclerosis, retractile mesenteritis, mesenteric Weber-Christian disease, liposclerotic mesenteritis, lipomatosis and lipogranuloma of the mesentery[1]
- A rare, benign, and chronic fibrosing inflammatory disease that affects the adipose tissue of the mesentery (of the small intestine and colon)[1].
- Occurs independently (specific cause unknown) or in association with other disorders[1]
Clinical Features
Differential Diagnosis
Evaluation
- Regional increase in mesenteric fat density on abdominal CT (i.e. “misty mesentery”)
- May be confirmed by surgical biopsy
Management
- Supportive ED treatment
There is no standardized treatment, and it may consist of anti-inflammatory or immunosuppressive agents. We recommend resection only when the advanced inflammatory changes become irreversible or in cases of bowel obstruction
- Chronic treatment includes workup of underlying etiology and consideration of medical therapy for severe/protracted disease (e.g. corticosteroids, cyclophosphamide, or azathioprine)
Disposition
- Outpatient
Prognosis
- Overall prognosis is usually good and recurrence seems to be rare[1]